Detalhe da pesquisa
1.
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Breast Cancer Res
; 26(1): 35, 2024 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38429789
2.
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
BMC Cancer
; 22(1): 1107, 2022 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309653
3.
Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Mol Carcinog
; 59(10): 1227-1240, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32816368
4.
RX-5902, a novel ß-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
BMC Cancer
; 20(1): 1063, 2020 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33148223
5.
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
BMC Cancer
; 18(1): 136, 2018 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29402316
6.
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.
Anticancer Drugs
; 29(9): 827-838, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30048249
7.
Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Invest New Drugs
; 35(1): 11-25, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27783255
8.
Population-level comparisons of gene regulatory networks modeled on high-throughput single-cell transcriptomics data.
Nat Comput Sci
; 4(3): 237-250, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438786
9.
Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL).
PLoS One
; 19(4): e0298808, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598488
10.
Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment.
Cancer Res Commun
; 3(9): 1899-1911, 2023 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37772994
11.
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors.
J Vis Exp
; (190)2022 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36591990
12.
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models.
Front Oncol
; 12: 877635, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36419897
13.
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
Mol Cancer Ther
; 21(3): 397-406, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965958
14.
Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
Mol Cancer Ther
; 20(10): 2049-2060, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34376578
15.
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma.
Front Oncol
; 11: 642328, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33869031
16.
Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.
Front Immunol
; 12: 607282, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33854497
17.
Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer.
Cancers (Basel)
; 12(3)2020 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32204315
18.
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.
Cell Death Dis
; 11(6): 443, 2020 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32513939
19.
Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
J Clin Endocrinol Metab
; 105(1)2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31513709
20.
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
Clin Cancer Res
; 26(17): 4633-4642, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32414750